Three Unstoppable Dividend Stocks to Buy Right Now: Abbott Laboratories, AbbVie, and Pfizer

Three unstoppable dividend stocks to buy right now are Abbott Laboratories, AbbVie, and Pfizer. Abbott Laboratories has a diversified business, long-term opportunities, and a 53-year streak of dividend increases. AbbVie is a blue-chip dividend stock with a robust portfolio and generous dividend increases. Pfizer has a strong dividend yield and a diversified business across pharmaceuticals and vaccines.

Investors seeking reliable income and long-term growth are often drawn to dividend stocks. Abbott Laboratories (ABT), AbbVie (ABBV), and Pfizer (PFE) are three such stocks that have proven their mettle in the dividend realm. Each company offers a unique set of advantages, making them attractive choices for investors.

Abbott Laboratories (ABT)

Abbott Laboratories, a medical device specialist, has demonstrated resilience despite the challenges posed by tariffs. The company's diversified business across medical devices, established pharmaceuticals, diagnostics, and nutrition ensures it can weather storms in any one segment. Abbott's FreeStyle Libre, a continuous glucose monitoring system, has been a key growth driver, and the company continues to innovate with new devices [1].

Abbott Laboratories boasts an impressive 53-year streak of consecutive dividend increases, earning it the title of Dividend King. While the forward dividend yield of 1.8% may seem modest, investors should focus on the company's rock-solid business and long-term prospects [1].

AbbVie (ABBV)

AbbVie, a blue-chip dividend stock, stands out for its robust portfolio and generous dividend increases. Since 2020, AbbVie has boosted its quarterly dividend by 39%, averaging a compound annual growth rate of 6.8% [1]. The company's free cash flow far exceeds its dividend payout, indicating ample room for further increases.

AbbVie's organic net revenue growth of 8% through the first half of 2025, despite varying performance across segments, underscores its strong business fundamentals. The company's above-average yield of 3.2% makes it an attractive choice for income investors [1].

Pfizer (PFE)

Pfizer, known for its high dividend yield, offers investors a forward yield of approximately 6.7%. Despite the looming patent cliff, Pfizer's 16-year streak of consecutive dividend increases and 347 quarters of dividend payments indicate a strong commitment to shareholders [1].

Pfizer's diverse product lineup includes key growth drivers like Cibinqo, Elrexfio, and Padcev, along with a promising pipeline of 108 programs in clinical development. The company's low forward price-to-earnings ratio of 8.3 further enhances its attractiveness [1].

Conclusion

Abbott Laboratories, AbbVie, and Pfizer offer investors a mix of strong business fundamentals, generous dividends, and long-term growth prospects. Each company's unique strengths make them compelling choices for income-seeking investors. However, as with any investment, thorough due diligence and consideration of individual financial circumstances are essential.

References

[1] The Globe and Mail. (2025, July 2). Three Unstoppable Dividend Stocks to Buy Right Now. Retrieved from https://www.theglobeandmail.com/investing/markets/stocks/ABT/pressreleases/34349290/3-unstoppable-dividend-stocks-to-buy-right-now/